Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed ...

Biotech stumbled in FY25, but we didn’t. HB Biotechnology kept its footing and delivered 23% outperformance in a tough market ...

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

Five acquisitions in 2025—including Cargo and Allakos—have put Concentra Biosciences in the spotlight. Learn what’s behind ...

If you have $1,000 to invest right now, you may be wondering where to get started. You could buy stocks that are flying high ...

Ardelyx (ARDX) is emerging as a compelling, yet risky, small-cap biotech opportunity. The company has made significant ...

Sonnet BioTherapeutics enters into an agreement to transform into the largest U.S.-based publicly listed company to hold HYPE.

Sonnet to merge with crypto-backed firm, forming Hyperliquid Strategies with $888 million in assets, plus HYPE blockchain ...

JNJ eyes Q2 growth with strong drug sales and new launches, but Stelara biosimilars and MedTech headwinds loom.

International companies are increasingly inking licensing deals with Chinese biotechs as concerns regarding drug pricing and ...

CSL shares have faced several headwinds over the past year. Here's what we can expect next from the biotech business.

BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out ...